Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × NSCLC × cemiplimab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 19 Lung Neoplasms 8 Squamous Cell Carcinoma of Head and Neck 5 Skin Neoplasms 5 Neoplasms 5 Urinary Bladder Neoplasms 4 Neoplasm Metastasis 4 Head and Neck Neoplasms 4 Colorectal Neoplasms 4 Carcinoma, Renal Cell 4 Carcinoma, Merkel Cell 4 Prostatic Neoplasms 3 Pancreatic Neoplasms 3 Mycosis Fungoides 3 Melanoma 3 Carcinoma, Squamous Cell 3 Breast Neoplasms 3 Adenocarcinoma 3 Triple Negative Breast Neoplasms 2 Rectal Neoplasms 2 Oropharyngeal Neoplasms 2 Mesothelioma, Malignant 2 Lymphoma, T-Cell 2 Lymphoma, Large-Cell, Anaplastic 2 Colonic Neoplasms 2 Carcinoma, Hepatocellular 2 Carcinoma 2 Vulvar Neoplasms 1 Uveal Melanoma 1 Uterine Cervical Neoplasms 1

Interventions

Drug Therapy 8 osimertinib 7 Pemetrexed 7 Radiotherapy 6 anlotinib 5 Carboplatin 5 Radiosurgery 4 Gefitinib 4 Docetaxel 4 tislelizumab 3 pembrolizumab 3 icotinib 3 aflutinib 3 Vinorelbine 3 Gemcitabine 3 Erlotinib Hydrochloride 3 Cisplatin 3 toripalimab 2 dacomitinib 2 apatinib 2 Tyrosine Kinase Inhibitors 2 Thalidomide 2 Surgical Procedures, Operative 2 S 1 (combination) 2 Platinum 2 Paclitaxel 2 Immune Checkpoint Inhibitors 2 Chemotherapy, Adjuvant 2 Chemoradiotherapy 2 Bevacizumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06865339 2025-09-10

TRIPL

Albert Einstein College of Medicine

Phase 2 Recruiting

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡